Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in its Phase 1 POLAR clinical trial for RP-3467, a Polθ ATPase inhibitor. The trial will evaluate RP-3467 alone and in combination with the PARP inhibitor olaparib. RP-3467 is Repare's fourth clinical program and has shown promising preclinical results, including complete and durable tumor regressions when combined with olaparib, without additional toxicities.
The POLAR trial (NCT06560632) aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467. It will enroll approximately 52 patients with advanced solid tumors, including ovarian, breast, prostate, and pancreatic cancers. The study's primary objectives are to evaluate safety and tolerability, and determine a recommended Phase 2 dose for the combination therapy.
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations. The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with variants of unknown significance (VUS).
Key findings include:
- Recommended Phase 2 dose: 160 mg camonsertib once-daily before 4Gy radiation on days 1-5
- At 2 months: Pathogenic group showed 2 complete responses (CR), 5 partial responses (PR), 4 stable disease (SD); VUS group had 1 PR, 4 SD
- At 6 months (9 evaluable patients): Pathogenic group reported 2 CR, 4 PR, 1 SD; VUS group had 1 SD, 1 progressive disease
The results suggest potential radiosensitization and higher clinical benefit in patients with pathogenic ATM mutations compared to those with VUS.
Repare Therapeutics presented new data at AACR's Ovarian Cancer Research Symposium, highlighting the impact of FBXW7, PPP2R1A, and CCNE1 alterations in metastatic ovarian and endometrial cancers. The analysis of approximately 2,000 patients revealed:
1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a median overall survival (mOS) of 26 months compared to 36 months for those without (Lunre BM-), representing a 28% decrease in mOS.
2. Endometrial cancer: Lunre BM+ patients had an mOS of 30 months versus 41 months for Lunre BM- patients, a 27% decrease in mOS.
These findings underscore the need for innovative treatments for patients with these biomarkers. Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biomarkers, with data expected in Q4 2024.
Repare Therapeutics (Nasdaq: RPTX) will present new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial at the ESMO Congress 2024 in Barcelona. The trial evaluates camonsertib monotherapy in patients with advanced solid tumors harboring ATM loss-of-function. TRESR (NCT04497116) is a first-in-human, multi-center, open-label study designed to establish the recommended Phase 2 dose and schedule, while assessing safety, pharmacokinetics, and preliminary anti-tumor activity. Dr. Benedito A. Carneiro from Brown University will deliver an oral presentation on September 14, sharing insights on camonsertib's performance in treating these specific cancer types.
Repare Therapeutics (Nasdaq: RPTX) announced a strategic reprioritization to focus on its clinical-stage oncology programs. The company plans to reduce its workforce by 25%, primarily from the preclinical group, expecting annual savings of $15 million and extending its cash runway into H2 2026. Key highlights include:
1. Upcoming data from the MYTHIC trial (lunresertib + camonsertib) in Q4 2024
2. Potential registrational trial for lunresertib in 2025
3. Initial data from MYTHIC trial Module 4 (lunresertib + Debio 0123) in 2025
4. Initial data from TRESR trial (camonsertib monotherapy) in 2025
5. Phase 1/2 trial for RP-1664 in pediatric neuroblastoma patients
6. Phase 1 trial initiation for RP-3467 in Q4 2024
The company aims to maximize value for patients and shareholders by focusing on its most promising precision oncology programs.
Repare Therapeutics (Nasdaq: RPTX), a leading clinical-stage precision oncology company, has announced its participation in two upcoming investor conferences in September 2024. The company's senior management team will be presenting at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 1:05 p.m. ET in New York, NY, for a fireside chat.
2. H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 9:00 a.m. ET in New York, NY, for a company overview.
Live webcasts of both presentations will be available on the company's website, with replays archived for at least 30 days.
Repare Therapeutics (Nasdaq: RPTX) reported Q2 2024 financial results and provided business updates. The company reiterated its guidance on the MYTHIC trial data readout for Q4 2024. The FDA granted Fast Track designation for lunresertib in combination with camonsertib in platinum-resistant ovarian cancer. Positive initial data from Phase 1 MINOTAUR trial was presented, and the first patient was dosed in the camonsertib monotherapy NSCLC expansion of Phase 1/2 TRESR trial.
Financially, Repare reported $1.1M in Q2 revenue and $53.5M for the first half of 2024. Net R&D expenses were $30.1M, and G&A expenses were $8.3M. The net loss was $34.8M or $0.82 per share.
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients, 40% of irinotecan-naïve patients received treatment for over nine months.
The recommended Phase 2 dose (RP2D) was established at 60mg BID lunresertib continuous plus standard FOLFIRI. Importantly, the safety profile was consistent with FOLFIRI alone, with the most common serious adverse events being neutropenia and leukopenia.
These findings, presented at the ESMO GI Cancers Congress, suggest lunresertib combined with FOLFIRI could offer a new treatment option for patients with CCNE1 amplification and FBXW7 mutations, which lack approved therapies.
Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in the expansion of its TRESR clinical trial, focusing on camonsertib monotherapy for non-small cell lung cancer (NSCLC) with ATM mutations. This expansion follows the rapid return of global rights to Repare. The TRESR trial aims to address the unmet need of over 5,000 patients with recurrent NSCLC in the US, UK, and top EU markets. Current treatments offer progression-free survival of around four months. The trial will enroll up to 20 patients to evaluate the efficacy of camonsertib at the recommended Phase 2 dose, with data expected in 2025.
Repare Therapeutics (Nasdaq: RPTX) has received Fast Track designation from the FDA for its combination therapy of lunresertib and camonsertib for treating platinum-resistant ovarian cancer in patients with specific genetic profiles (CCNE1 amplification, FBXW7, or PPP2R1A mutations). This treatment is currently in Phase 1 dose expansion trials. The FDA previously granted Fast Track designation for the same combination in treating endometrial cancer. Repare plans to present data from these trials in the fourth quarter of 2024, involving 20-30 patients each for ovarian and endometrial cancers. The Fast Track designation aims to expedite the development and review processes to bring significant new therapies to patients sooner.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
